{"id":"W2569254611","doi":"10.5489/cuaj.4292","title":"Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Cabozantinib; Axitinib; Everolimus; Lenvatinib; Medicine; Renal cell carcinoma; Sunitinib; Nivolumab; Vascular endothelial growth factor; Pazopanib; Oncology; Targeted therapy; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Cancer research; VEGF receptors; Sorafenib; Immunotherapy; Receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005167708,0.0005624683,0.001398515,0.002630669,0.0002942176,0.0008741253,0.000778986,0.0009195248,0.003500144],"category_scores_gemma":[0.0008399856,0.000163953,0.0006915448,0.001899799,0.0003255432,0.0008743261,0.0004529989,0.00127922,0.0009376081],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005442742,"about_ca_system_score_gemma":0.001014679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001861836,"about_ca_topic_score_gemma":0.005386102,"domain_scores_codex":[0.9998181,0.00004081669,0.00003637104,0.00002665499,0.00006274584,0.00001533183],"domain_scores_gemma":[0.9996974,0.0001667139,0.0000572388,0.000005763574,0.00005266402,0.00002020807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005897125,0.00006805069,0.0002720766,0.02909943,0.0001558189,0.0005194501,0.00008121409,0.0003852037,0.0005944902,0.002493025,0.02284868,0.9434236],"study_design_scores_gemma":[0.0000372352,0.00009297138,0.001537867,0.01785289,0.0003551547,0.005658058,0.0001427958,0.0001462287,0.0003497635,0.001841512,0.9719588,0.0000268023],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000786243,0.9991906,0.00004183646,0.0001383101,0.00005422793,0.000002711412,0.000008843692,0.000002107353,0.0004826786],"genre_scores_gemma":[0.0008083107,0.9986891,0.00008219599,0.0001149515,0.00007339079,0.000003674505,0.00002195421,6.544922e-7,0.0002057911],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003500144,"threshold_uncertainty_score":0.01170909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01977647260996031,"score_gpt":0.240965493428227,"score_spread":0.2211890208182667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}